Literature DB >> 21046118

Pediatric patients receiving ABO-incompatible living related liver transplantation exhibit higher serum transforming growth factor-β1, interferon-γ and interleukin-2 levels.

Mohamed Hamed Hussein1, Takashi Hashimoto, Ghada AbdEl-Hamid Daoud, Takazumi Kato, Masahito Hibi, Hirokazu Tomishige, Fujio Hara, Tatsuya Suzuki, Yoko Nakajima, Tatenobu Goto, Tetsuya Ito, Ineko Kato, Atsushi Sugioka, Hajime Togari.   

Abstract

BACKGROUND: ABO-incompatible liver transplantation (LTx) is becoming more common in response to the paucity of liver allografts. Several studies have expressed concern about the effect of ABO compatibility on graft survival.
PURPOSE: To evaluate the differences in serum cytokine levels between ABO-incompatible (ABO-i) and ABO-compatible (ABO-c; includes ABO-compatible and identical) pediatric LTx recipients during regular outpatient follow-up. Note that, in the field of organ transplantation, transplants are categorized as incompatible, compatible or identical; accordingly, these are the terms we use in the paper.
MATERIALS AND METHODS: A clinical outpatient study measuring serum transforming growth factor (TGF)-β1, interferon (IFN)-γ, interleukin (IL)-2 and IL-10 in 43 living related liver transplantation (LRLT) recipients, of whom 36 received ABO-c LRLT (34 were ABO-identical and 2 were non-identical) and 7 ABO-i LRLT. Serum glutamic pyruvic transaminase, glutamic oxaloacetic transaminase, gamma-glutamyl transpeptidase, alkaline phosphatase, lactate dehydrogenase and bilirubin were measured as part of the patients' regular follow-up visits.
RESULTS: There were no differences between the ABO-c and ABO-i groups in terms of recipient's age [mean 12.6 vs. 11.1 years (y)], post-LTx duration (mean 7.3 vs. 7.3 y), donor's age (mean 35.5 vs. 34.6 y), body weight (28.9 ± 2.9 vs. 27.9 ± 6.9 kg), or gender (19 female and 17 male vs. 4 female and 3 male). Serum TGF-β1, IFN-γ and IL-2 were significantly higher in the ABO-i group than in the ABO-c group. IL-10, however, did not differ between the two groups. There was a tendency toward higher γGTP levels in the ABO-i group, but this difference did not reach significance.
CONCLUSION: ABO-incompatible LRLTx patients have higher serum TGF-β1, IFN-γ and IL-2 levels as measured at regular outpatient visits. As a result, they face a higher risk of T-helper 1 cell polarization, which could make graft rejection more likely.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21046118     DOI: 10.1007/s00383-010-2784-1

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  19 in total

1.  Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries.

Authors:  C-L Lin; F-S Wang; Y-R Kuo; Y-T Huang; H-C Huang; Y-C Sun; Y-H Kuo
Journal:  Kidney Int       Date:  2006-05       Impact factor: 10.612

Review 2.  Promising recent data on ABO incompatible liver transplantation: restrictions may apply.

Authors:  Johann Pratschke; Stefan G Tullius
Journal:  Transpl Int       Date:  2007-08       Impact factor: 3.782

3.  Daily determinations of serum lymphotoxin allows for accurate early diagnosis of hepatic allograft rejection.

Authors:  H Sankary; A Chong; E Frye; P Scuderi; P Foster; L McChesney; J Williams
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

Review 4.  Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies.

Authors:  S L Friedman
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

5.  Increased expression of interleukin-4 during liver allograft rejection.

Authors:  F Conti; Y Calmus; E Rouer; P Gaulard; A Louvel; D Houssin; E S Zafrani
Journal:  J Hepatol       Date:  1999-05       Impact factor: 25.083

6.  Successful use of an enhanced immunosuppressive protocol with plasmapheresis for ABO-incompatible mismatched grafts in liver transplant recipients.

Authors:  E Mor; D Skerrett; C Manzarbeitia; P A Sheiner; M E Schwartz; S Emre; S N Thung; C M Miller
Journal:  Transplantation       Date:  1995-04-15       Impact factor: 4.939

7.  Interleukin-15 production during liver allograft rejection in humans.

Authors:  Filomena Conti; Jerome Frappier; Sebastien Dharancy; Christiane Chereau; Didier Houssin; Bernard Weill; Yvon Calmus
Journal:  Transplantation       Date:  2003-07-15       Impact factor: 4.939

8.  Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation.

Authors:  Hiroto Egawa; Fumitaka Oike; Leo Buhler; A M James Shapiro; Sachiko Minamiguchi; Hironori Haga; Kenji Uryuhara; Tetsuya Kiuchi; Satoshi Kaihara; Koichi Tanaka
Journal:  Transplantation       Date:  2004-02-15       Impact factor: 4.939

9.  ABO-incompatible liver transplantation for critically ill adult patients.

Authors:  Christian Toso; Mohammed Al-Qahtani; Faisal A Alsaif; David L Bigam; Glenda A Meeberg; A M James Shapiro; Vincent G Bain; Norman M Kneteman
Journal:  Transpl Int       Date:  2007-05-22       Impact factor: 3.782

10.  Management of anti-allogeneic antibody elimination by apheresis in living donor liver transplantation.

Authors:  Naoki Kawagishi; Ikuo Takeda; Shigehito Miyagi; Kazushige Satoh; Yorihiro Akamatsu; Satoshi Sekiguchi; Keisei Fujimori; Toshinobu Sato; Susumu Satomi
Journal:  Ther Apher Dial       Date:  2007-10       Impact factor: 1.762

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.